{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:32:22Z","timestamp":1790821942405,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T00:00:00Z","timestamp":1709164800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T00:00:00Z","timestamp":1709164800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s40265-024-02007-6","type":"journal-article","created":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T22:02:18Z","timestamp":1709157738000},"page":"467-472","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Apadamtase Alfa: First Approval"],"prefix":"10.1007","volume":"84","author":[{"given":"Young-A.","family":"Heo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,29]]},"reference":[{"issue":"3","key":"2007_CR1","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s12185-023-03552-8","volume":"117","author":"M Kubo","year":"2023","unstructured":"Kubo M, Matsumoto M. Frontiers in pathophysiology and management of thrombotic thrombocytopenic purpura. Int J Hematol. 2023;117(3):331\u201340.","journal-title":"Int J Hematol"},{"issue":"10","key":"2007_CR2","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.3390\/genes14101956","volume":"14","author":"S Nusrat","year":"2023","unstructured":"Nusrat S, Beg K, Khan O, et al. Hereditary thrombotic thrombocytopenic purpura. Genes (Basel). 2023;14(10):1956.","journal-title":"Genes (Basel)."},{"issue":"3","key":"2007_CR3","doi-asserted-by":"publisher","first-page":"536","DOI":"10.3390\/jcm10030536","volume":"10","author":"S Sukumar","year":"2021","unstructured":"Sukumar S, L\u00e4mmle B, Cataland SR. Thrombotic thrombocytopenic purpura: pathophysiology, diagnosis, and management. J Clin Med. 2021;10(3):536.","journal-title":"J Clin Med"},{"key":"2007_CR4","doi-asserted-by":"publisher","first-page":"24","DOI":"10.21037\/aob-22-17","volume":"8","author":"K Sakai","year":"2023","unstructured":"Sakai K, Hamada E, Kokame K, et al. Congenital thrombotic thrombocytopenic purpura: genetics and emerging therapies. Ann Blood. 2023;8:24.","journal-title":"Ann Blood."},{"issue":"11\u201312","key":"2007_CR5","doi-asserted-by":"publisher","first-page":"160","DOI":"10.18632\/oncoscience.380","volume":"4","author":"M Scully","year":"2017","unstructured":"Scully M, Hibbard C, Ewenstein B. Recombinant ADAMTS 13 in thrombotic thrombocytopenic purpura. Oncoscience. 2017;4(11\u201312):160\u20131.","journal-title":"Oncoscience."},{"key":"2007_CR6","unstructured":"US Food & Drug Administration. FDA approves first treatment for patients with rare inherited blood clotting disorder [media release]. 9 Nov 2023. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-patients-rare-inherited-blood-clotting-disorder."},{"key":"2007_CR7","unstructured":"Takeda. ADZYNMA (ADAMTS13, recombinant-krhn) lyophilized powder for injection, for intravenous use. 2023. https:\/\/content.takeda.com\/?contenttype=PI&product=ADZ&language=ENG&country=USA&documentnumber=1. Accessed 13 Nov 2023."},{"key":"2007_CR8","unstructured":"Takeda. Takeda\u2019s ADZYNMA (ADAMTS13, recombinant-krhn) approved by U.S. FDA as the first and only recombinant ADAMTS13 enzyme replacement therapy for the treatment of congenital thrombotic thrombocytopenic purpura (cTTP) [media release]. 9 Nov 2023. https:\/\/www.takeda.com\/."},{"issue":"25","key":"2007_CR9","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1056\/NEJMoa2211113","volume":"387","author":"LM Asmis","year":"2022","unstructured":"Asmis LM, Serra A, Krafft A, et al. Recombinant ADAMTS13 for hereditary thrombotic thrombocytopenic purpura. N Engl J Med. 2022;387(25):2356\u201361.","journal-title":"N Engl J Med"},{"key":"2007_CR10","unstructured":"Baxter International I. Baxter adds recombinant protein to specialty therapeutics portfolio [media release]. 16 Oct 2007. http:\/\/www.baxter.com."},{"key":"2007_CR11","unstructured":"Shire. Shire completes combination with Baxalta creating the global leader in rare diseases and highly specialized conditions [media release]. 3 Jun 2016. http:\/\/www.shire.com."},{"key":"2007_CR12","unstructured":"Takeda. Takeda completes acquisition of Shire, becoming a global, values-based, R&D-driven biopharmaceutical leader [media release]. 8 Jan 2019. http:\/\/www.takeda.com."},{"key":"2007_CR13","unstructured":"Orsini Healthcare Specialty Pharmacy. Orsini specialty pharmacy selected as distribution partner for Adzynma (ADAMTS13, recombinant-krhn), a newly approved treatment for an ultra-rare blood clotting disorder [media release]. 20 Nov 2023. http:\/\/www.orsinispecialtypharmacy.com."},{"key":"2007_CR14","unstructured":"Takeda. Form 20-F FY2022. 2023. https:\/\/assets-dam.takeda.com\/image\/upload\/v1687949092\/Global\/Investor\/form20-f\/E_FY2022_Form_20-F.pdf. Accessed 24 Nov 2023."},{"issue":"11","key":"2007_CR15","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1111\/jth.13137","volume":"13","author":"B Plaimauer","year":"2015","unstructured":"Plaimauer B, Schiviz A, Kaufmann S, et al. Neutralization of inhibitory antibodies and restoration of therapeutic ADAMTS-13 activity levels in inhibitor-treated rats by the use of defined doses of recombinant ADAMTS-13. J Thromb Haemost. 2015;13(11):2053\u201362.","journal-title":"J Thromb Haemost"},{"issue":"7","key":"2007_CR16","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1111\/jth.13341","volume":"14","author":"A Kopi\u0107","year":"2016","unstructured":"Kopi\u0107 A, Benamara K, Piskernik C, et al. Preclinical assessment of a new recombinant ADAMTS-13 drug product (BAX930) for the treatment of thrombotic thrombocytopenic purpura. J Thromb Haemost. 2016;14(7):1410\u20139.","journal-title":"J Thromb Haemost"},{"issue":"11","key":"2007_CR17","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1161\/ATVBAHA.115.306014","volume":"35","author":"C Tersteeg","year":"2015","unstructured":"Tersteeg C, Schiviz A, De Meyer SF, et al. Potential for recombinant ADAMTS13 as an effective therapy for acquired thrombotic thrombocytopenic purpura. Arterioscler Thromb Vasc Biol. 2015;35(11):2336\u201342.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"2007_CR18","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.jtha.2022.10.016","volume":"21","author":"P Rossato","year":"2023","unstructured":"Rossato P, Glantschnig H, Canneva F, et al. Treatment with recombinant ADAMTS13, alleviates hypoxia\/reoxygenation-induced pathologies in a mouse model of human sickle cell disease. J Thromb Haemost. 2023;21(2):269\u201375.","journal-title":"J Thromb Haemost"},{"issue":"11","key":"2007_CR19","doi-asserted-by":"publisher","first-page":"2650","DOI":"10.3324\/haematol.2021.280233","volume":"107","author":"P Rossato","year":"2022","unstructured":"Rossato P, Federti E, Matte A, et al. Evidence of protective effects of recombinant ADAMTS13 in a humanized model of sickle cell disease. Haematologica. 2022;107(11):2650\u201360.","journal-title":"Haematologica"},{"issue":"14","key":"2007_CR20","doi-asserted-by":"publisher","first-page":"11782","DOI":"10.3390\/ijms241411782","volume":"24","author":"D Gao","year":"2023","unstructured":"Gao D, Zhou Z, Ma R, et al. Recombinant ADAMTS-13 improves survival of mice subjected to endotoxemia. Int J Mol Sci. 2023;24(14):11782.","journal-title":"Int J Mol Sci"},{"issue":"19","key":"2007_CR21","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1182\/blood-2017-06-788026","volume":"130","author":"M Scully","year":"2017","unstructured":"Scully M, Kn\u00f6bl P, Kentouche K, et al. Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura. Blood. 2017;130(19):2055\u201363.","journal-title":"Blood"},{"key":"2007_CR22","doi-asserted-by":"crossref","unstructured":"Patel M, Barriere O, Diderichsen P, et al. Population pharmacokinetics and exposure-response analyses to demonstrate the link of causality between ADAMTS13 and the clinical effects of recombinant ADAMTS13 compared to plasma-based therapies [abstract no. 1260]. In: 65th ASH annual meeting & exposition. 2023.","DOI":"10.1182\/blood-2023-189314"},{"key":"2007_CR23","doi-asserted-by":"crossref","unstructured":"Cataland S, Patel M, Mellg\u00e5rd B, et al. Pharmacokinetic characteristics of ADAMTS13 in patients with congenital thrombotic thrombocytopenic purpura: interim results from a phase 3 randomized, controlled, open-label, crossover study [abstract no. OC 14.2]. Res Pract Thromb Haemost. 2023;7(Suppl 2):180\u20131.","DOI":"10.1016\/j.rpth.2023.100531"},{"key":"2007_CR24","doi-asserted-by":"crossref","unstructured":"Scully M, Windyga J, Mellg\u00e5rd B, et al. Phase 3 prospective, randomized, controlled, open-label, multicenter, crossover study of recombinant ADAMTS13 in patients with congenital thrombotic thrombocytopenic purpura [abstract no. OC 14.1]. Res Pract Thromb Haemost. 2023;7(Suppl 2):182\u20133.","DOI":"10.1016\/j.rpth.2023.100533"},{"key":"2007_CR25","doi-asserted-by":"crossref","unstructured":"Coppo P, Patwari P, Mellg\u00e5rd B, et al. Recombinant ADAMTS13 prophylaxis in patients with congenital thrombotic thrombocytopenic purpura: interim analysis from phase 3B continuation study [abstract no. OC 14.4]. Res Pract Thromb Haemost. 2023;7(Suppl 2):183.","DOI":"10.1016\/j.rpth.2023.100534"},{"key":"2007_CR26","doi-asserted-by":"crossref","unstructured":"Scully M, Ortel T, Yu Z, et al. Recombinant ADAMTS13 for the treatment of acute TTP events in patients with congenital thrombotic thrombocytopenic purpura: results from the phase 3 randomized, controlled, crossover study and the phase 3b continuation study [abstract no. 692 plus oral presentation]. In: 65th ASH annual meeting & exposition. 2023.","DOI":"10.1182\/blood-2023-188996"},{"key":"2007_CR27","doi-asserted-by":"crossref","unstructured":"Scully M, Baptista J, Bhattacharya I, et al. Phase 2 randomized, placebo-controlled, double-blind, multicenter study of recombinant ADAMTS13 in patients with immune-mediated thrombotic thrombocytopenic purpura [abstract no. S305]. HemaSphere. 2023;7(S3):e8651306.","DOI":"10.1097\/01.HS9.0000968132.86513.06"},{"key":"2007_CR28","doi-asserted-by":"crossref","unstructured":"Kanter J, Patwari P, Desai P, et al. Safety and pharmacokinetics of recombinant ADAMTS13 in patients with sickle cell disease: a phase 1 randomized, double-blind, placebo-controlled study [abstract no. 149 plus oral presentation]. In: 65th ASH annual meeting & exposition. 2023.","DOI":"10.1182\/blood-2023-189090"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-02007-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-024-02007-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-02007-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T23:39:13Z","timestamp":1715989153000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-024-02007-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,29]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["2007"],"URL":"https:\/\/doi.org\/10.1007\/s40265-024-02007-6","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,29]]},"assertion":[{"value":"29 February 2024","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Young-A Heo is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}